The Effect of Scaling with Photodynamic Therapy on IL-6 and IL-1B levels in patients with Peri-implantitis

Not Applicable

Recruiting

Conditions: Peri-implantitis.
Post-osseointegration biological failure of dental implant
M27.62

Registration Number: IRCT20210212050339N1

Lead Sponsor: Islamic Azad University

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 66

Inclusion Criteria

At least one implant with peri-implantitis
The implant has been in function for at least one year
Screw-type implants with rough surface
Partial edentulous patients with healthy or treated periodontal condition who are in maintenance care program.
Total plaque score = 25
18-80 years of age

Exclusion Criteria

Use of Antibacterial or Non-steroidal Anti-inflammatory drugs within 3 months prior to diagnosis
Implant mobility
Pregnancy or breastfeeding
History of autoimmune diseases, malignancy, cardiovascular insufficiency, or acute diseases of other organs
History of Peri-implantitis or Periodontal treatment in last 6 months
Uncontrolled Diabetes (HbA1c > 7%)
Tobacco use
Use of Systemic Antibiotic Therapy for Prophylaxis of Endocarditis
Infectious diseases such as HIV, TB and Hepatitis
Failure to sign a written consent
Those treated with any drugs which may affect soft tissue conditions; such as Phenytoin, Cyclosporine, etc. for 2 weeks or more in a month, before the initial evaluation.
Head and neck radiotherapy
Alcohol or drug abuse

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Interleukin 1-b Levels in Gingival Crevicular Fluid. Timepoint: At baseline, 3 months, and 6 months after treatment. Method of measurement: The Enzyme-linked Immunosorbent Assay test.;Interleukin 1-b Levels in Gingival Crevicular Fluid. Timepoint: At baseline, 3 months, and 6 months after treatment. Method of measurement: The Enzyme-linked Immunosorbent Assay test.

Secondary Outcome Measures